We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eli Lilly and Company, Vir Biotechnology, and GlaxoSmithKline (GSK) have entered into a partnership to analyse a combination of two therapies in low-risk patients with mild to moderate Covid-19.